anti-integrin beta-6/MMAE antibody-drug conjugate SGN-B6A

{
  "id": "MLC-T-ONC-010827",
  "term": "anti-integrin beta-6/MMAE antibody-drug conjugate SGN-B6A",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a humanized antibody targeting integrin beta-6 and conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-integrin beta-6/MMAE ADC SGN-B6A targets and binds to integrin beta-6 on the surface of tumor cells. Following internalization of SGN-B6A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in integrin beta-6-expressing tumor cells. Integrin beta-6 is a subunit of integrin alpha-V beta-6 (aVb6). Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.",
  "synonyms": [
    "anti-integrin beta-6 antibody-drug conjugate SGN-B6A",
    "anti-integrin beta-6/MMAE ADC SGN-B6A",
    "anti-integrin beta-6-MMAE ADC SGN-B6A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-integrin-beta-6-mmae-antibody-drug-conjugate-sgn-b6a/"
}